Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
HG.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FD.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
FD.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.44NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.44NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.5.26NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.26NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
GN.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
GN.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FW.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
FW.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FY.1.2.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FY.1.2.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XDV.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XDV.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JN.1.48.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.48.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
LR.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
LR.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
LF.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
LF.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
LB.1.4.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
LB.1.4.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JN.1.64NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.64NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JN.1.13.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.13.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JN.1.32.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.32.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JN.1.4.7NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.4.7NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.2.86.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.2.86.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JN.1.34NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.34NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
HK.3.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
HK.3.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
LA.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
LA.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
LF.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
LF.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
KP.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
KP.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
KP.2.16NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
KP.2.16NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
KP.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
KP.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XDP.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used